Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2024 The trial protocol was amended to include 2 sub-studies, sub-study 1 and sub-study 2 which includes cohort 2a and 2b, hence there was a change in treatment arms from 7 to 11 and change in the primary and secondary endpoints and inclusion/ exclusion criteria.
14 Oct 2024 Planned End Date changed from 31 Dec 2026 to 30 Sep 2029.
14 Oct 2024 Planned primary completion date changed from 31 Dec 2026 to 30 Sep 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com